TDO2 and neoplasm: AHR activation through kynurenine causes immunosuppression and a tumor-promoting microenvironment in many cancer entities, representing a prominent immune escape mechanism.492 Therefore, pharmacological targeting of the IDO1/TDO2-AHR pathway may be a promising therapeutic strategy in immuno-oncology.